131 related articles for article (PubMed ID: 23216087)
21. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats.
Jin F; Wu Q; Lu YF; Gong QH; Shi JS
Eur J Pharmacol; 2008 Dec; 600(1-3):78-82. PubMed ID: 18940189
[TBL] [Abstract][Full Text] [Related]
22. Serofendic acid prevents 6-hydroxydopamine-induced nigral neurodegeneration and drug-induced rotational asymmetry in hemi-parkinsonian rats.
Inden M; Kitamura Y; Kondo J; Hayashi K; Yanagida T; Takata K; Tsuchiya D; Yanagisawa D; Nishimura K; Taniguchi T; Shimohama S; Sugimoto H; Akaike A
J Neurochem; 2005 Nov; 95(4):950-61. PubMed ID: 16135081
[TBL] [Abstract][Full Text] [Related]
23. Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease.
Ambrosi G; Armentero MT; Levandis G; Bramanti P; Nappi G; Blandini F
Brain Res Bull; 2010 Apr; 82(1-2):29-38. PubMed ID: 20100549
[TBL] [Abstract][Full Text] [Related]
24. Apelin-13 ameliorates cognitive impairments in 6-hydroxydopamine-induced substantia nigra lesion in rats.
Haghparast E; Esmaeili-Mahani S; Abbasnejad M; Sheibani V
Neuropeptides; 2018 Apr; 68():28-35. PubMed ID: 29329678
[TBL] [Abstract][Full Text] [Related]
25. Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats.
Marin C; Jiménez A; Tolosa E; Bonastre M; Bové J
Synapse; 2004 Feb; 51(2):140-50. PubMed ID: 14618681
[TBL] [Abstract][Full Text] [Related]
26. Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA.
Dominguez-Meijide A; Villar-Cheda B; Garrido-Gil P; Sierrra-Paredes G; Guerra MJ; Labandeira-Garcia JL
Neuropharmacology; 2014 Jan; 76 Pt A():156-68. PubMed ID: 23973568
[TBL] [Abstract][Full Text] [Related]
27. Post-lesion administration of 7-NI attenuated motor and non-motor deficits in 6-OHDA induced bilaterally lesioned female rat model of Parkinson's disease.
Kumari R; Kumar JB; Luthra PM
Neurosci Lett; 2015 Mar; 589():191-5. PubMed ID: 25528406
[TBL] [Abstract][Full Text] [Related]
28. Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents.
Nie S; Xu Y; Chen G; Ma K; Han C; Guo Z; Zhang Z; Ye K; Cao X
Neuropharmacology; 2015 Dec; 99():448-58. PubMed ID: 26282118
[TBL] [Abstract][Full Text] [Related]
29. Stimulation of delta opioid receptors located in substantia nigra reticulata but not globus pallidus or striatum restores motor activity in 6-hydroxydopamine lesioned rats: new insights into the role of delta receptors in parkinsonism.
Mabrouk OS; Volta M; Marti M; Morari M
J Neurochem; 2008 Dec; 107(6):1647-59. PubMed ID: 19094058
[TBL] [Abstract][Full Text] [Related]
30. Neuroprotective effect of silymarin in 6-hydroxydopamine hemi-parkinsonian rat: involvement of estrogen receptors and oxidative stress.
Baluchnejadmojarad T; Roghani M; Mafakheri M
Neurosci Lett; 2010 Aug; 480(3):206-10. PubMed ID: 20600617
[TBL] [Abstract][Full Text] [Related]
31. Neurosteroid allopregnanolone attenuates cognitive dysfunctions in 6-OHDA-induced rat model of Parkinson's disease.
Nezhadi A; Sheibani V; Esmaeilpour K; Shabani M; Esmaeili-Mahani S
Behav Brain Res; 2016 May; 305():258-64. PubMed ID: 26970579
[TBL] [Abstract][Full Text] [Related]
32. Effect of adenosine A2A receptor antagonists on motor disorders induced by 6-hydroxydopamine in rat.
Reyhani-Rad S; Mahmoudi J
Acta Cir Bras; 2016 Feb; 31(2):133-7. PubMed ID: 26959623
[TBL] [Abstract][Full Text] [Related]
33. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
[TBL] [Abstract][Full Text] [Related]
34. Nonmotor symptoms in Parkinson's disease: investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model.
Branchi I; D'Andrea I; Armida M; Cassano T; Pèzzola A; Potenza RL; Morgese MG; Popoli P; Alleva E
J Neurosci Res; 2008 Jul; 86(9):2050-61. PubMed ID: 18335518
[TBL] [Abstract][Full Text] [Related]
35. The sympathetic nervous system is controlled by transient receptor potential vanilloid 1 in the regulation of body temperature.
Alawi KM; Aubdool AA; Liang L; Wilde E; Vepa A; Psefteli MP; Brain SD; Keeble JE
FASEB J; 2015 Oct; 29(10):4285-98. PubMed ID: 26136480
[TBL] [Abstract][Full Text] [Related]
36. Differing short-term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson's disease.
Kreisler A; Duhamel A; Vanbesien-Mailliot C; Destée A; Bordet R
Behav Pharmacol; 2010 May; 21(3):194-205. PubMed ID: 20440202
[TBL] [Abstract][Full Text] [Related]
37. Caffeine neuroprotective effects on 6-OHDA-lesioned rats are mediated by several factors, including pro-inflammatory cytokines and histone deacetylase inhibitions.
Machado-Filho JA; Correia AO; Montenegro AB; Nobre ME; Cerqueira GS; Neves KR; Naffah-Mazzacoratti Mda G; Cavalheiro EA; de Castro Brito GA; de Barros Viana GS
Behav Brain Res; 2014 May; 264():116-25. PubMed ID: 24525422
[TBL] [Abstract][Full Text] [Related]
38. Protective effect of L-kynurenine and probenecid on 6-hydroxydopamine-induced striatal toxicity in rats: implications of modulating kynurenate as a protective strategy.
Silva-Adaya D; Pérez-De La Cruz V; Villeda-Hernández J; Carrillo-Mora P; González-Herrera IG; García E; Colín-Barenque L; Pedraza-Chaverrí J; Santamaría A
Neurotoxicol Teratol; 2011; 33(2):303-12. PubMed ID: 20933078
[TBL] [Abstract][Full Text] [Related]
39. Blocking of Transient Receptor Potential Vanilloid 1 (TRPV1) promotes terminal mitophagy in multiple myeloma, disturbing calcium homeostasis and targeting ubiquitin pathway and bortezomib-induced unfolded protein response.
Beider K; Rosenberg E; Dimenshtein-Voevoda V; Sirovsky Y; Vladimirsky J; Magen H; Ostrovsky O; Shimoni A; Bromberg Z; Weiss L; Peled A; Nagler A
J Hematol Oncol; 2020 Nov; 13(1):158. PubMed ID: 33239060
[TBL] [Abstract][Full Text] [Related]
40. Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease.
Armentero MT; Fancellu R; Nappi G; Bramanti P; Blandini F
Neurobiol Dis; 2006 Apr; 22(1):1-9. PubMed ID: 16289868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
